Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 1/2004

01.01.2004 | Original Article

Cytokines IL-1α, IL-6, and GM-CSF constitutively secreted by oral squamous carcinoma induce down-regulation of CD80 costimulatory molecule expression: restoration by interferon γ

verfasst von: Giovana R. Thomas, Zhong Chen, Elena Leukinova, Carter Van Waes, Judy Wen

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 1/2004

Einloggen, um Zugang zu erhalten

Abstract

We previously characterized the expression of CD80 in different murine head and neck squamous cell carcinoma (HNSCC) clones derived following tumor progression in the absence of T cell–mediated immunity in severe combined immunodeficient (SCID) mice. We found that HNSCCs that did not express CD80 grew as progressors, while those that expressed CD80 were regressors when grown in immune-competent animals. In the present study, we characterized expression of a repertoire of immunoregulatory cytokines in these HNSCC lines, and found that HNSCCs that express cytokines IL-1α, IL-6, and GM-CSF do not express CD80, suggesting the hypothesis that these cytokines may down-modulate expression of CD80. Cytokine-conditioned medium from progressor HNSCC and recombinant IL-1α, IL-6, and GM-CSF caused a reduction of CD80 expression in regressor HNSCCs without affecting proliferation. Conversely, the decrease in CD80 expression in progressor HNSCCs could be restored by IFN-γ, a known inducer of CD80 expression. These data strongly suggest that high levels of cytokines IL-1α, IL-6, and GM-CSF expressed by tumor cells can down-regulate CD80 expression in HNSCC, and that IFN-γ can independently stimulate expression. These data provide evidence for a novel mechanism of cytokine-mediated down-modulation of CD80 during malignant progression of HNSCC that can be restored by IFN-γ.
Literatur
1.
Zurück zum Zitat Lenschow DJ, Walunas TL, Bluestone JA (1996) CD28/B7 system of T cell costimulation. Ann Rev Immunol 14:233CrossRef Lenschow DJ, Walunas TL, Bluestone JA (1996) CD28/B7 system of T cell costimulation. Ann Rev Immunol 14:233CrossRef
2.
Zurück zum Zitat Sperling AI, Bluestone JA (1996) The complexities of T cell costimulation: CD28 and beyond. Immunol Rev 153:155PubMed Sperling AI, Bluestone JA (1996) The complexities of T cell costimulation: CD28 and beyond. Immunol Rev 153:155PubMed
3.
4.
Zurück zum Zitat Schwartz RH (1996) Models of T cell anergy: is there a common molecular mechanism? J Exp Med 184:1PubMed Schwartz RH (1996) Models of T cell anergy: is there a common molecular mechanism? J Exp Med 184:1PubMed
5.
Zurück zum Zitat Cozzolino F, Torcia M, Carossino A, Giordani R, Selli C, Talini G, Reali E, Novelli A, Pistoia V, Ferrarini M (1987) Characterization of cells from invaded lymph nodes in patients with solid tumors: lymphokine requirement for tumor-specific lymphoproliferative responses. J Exp Med 166:303PubMed Cozzolino F, Torcia M, Carossino A, Giordani R, Selli C, Talini G, Reali E, Novelli A, Pistoia V, Ferrarini M (1987) Characterization of cells from invaded lymph nodes in patients with solid tumors: lymphokine requirement for tumor-specific lymphoproliferative responses. J Exp Med 166:303PubMed
6.
Zurück zum Zitat Burkey BB, Omann GM, Wolf GT (1991) Intracellular calcium changes associated with in vitro lymphokine activated killer and natural killer cell cytotoxicity. Arch Otolaryngol Head Neck Surg 117:1281PubMed Burkey BB, Omann GM, Wolf GT (1991) Intracellular calcium changes associated with in vitro lymphokine activated killer and natural killer cell cytotoxicity. Arch Otolaryngol Head Neck Surg 117:1281PubMed
7.
Zurück zum Zitat Bennet S, Futrell J, Roth J, Hoye R, Kecham A (1971) Prognostic significance of histologic host response in cancer in the larynx or hypopharynx. Cancer 28:1255PubMed Bennet S, Futrell J, Roth J, Hoye R, Kecham A (1971) Prognostic significance of histologic host response in cancer in the larynx or hypopharynx. Cancer 28:1255PubMed
8.
Zurück zum Zitat Lang S, Atarashi Y, Nishioka Y, Stanson J, Meidenbauer N, Whiteside TL (2000) B7-1 on human carcinomas: costimulation of T cells and enhanced tumor-induced T-cell death. Cellular Immunol 201(2):132CrossRef Lang S, Atarashi Y, Nishioka Y, Stanson J, Meidenbauer N, Whiteside TL (2000) B7-1 on human carcinomas: costimulation of T cells and enhanced tumor-induced T-cell death. Cellular Immunol 201(2):132CrossRef
9.
Zurück zum Zitat Lang S, Whiteside TL, Lebeau A, Zeidler R, Mack B, Wollenberg B (1999) Impairment of T-cell activation in head and neck cancer in situ and in vitro: strategies for an immune restoration. Arch Otolaryngol Head Neck Surg 125(1): 82PubMed Lang S, Whiteside TL, Lebeau A, Zeidler R, Mack B, Wollenberg B (1999) Impairment of T-cell activation in head and neck cancer in situ and in vitro: strategies for an immune restoration. Arch Otolaryngol Head Neck Surg 125(1): 82PubMed
10.
Zurück zum Zitat Thomas GR, Chen Z, Oechsli M, Hendler JH, Van Waes C (1999) Decreased expression of CD80 is a marker for increased tumorigenicity in a new murine model of oral squamous-cell carcinoma. Int J Cancer 82:377CrossRefPubMed Thomas GR, Chen Z, Oechsli M, Hendler JH, Van Waes C (1999) Decreased expression of CD80 is a marker for increased tumorigenicity in a new murine model of oral squamous-cell carcinoma. Int J Cancer 82:377CrossRefPubMed
11.
Zurück zum Zitat Smith CW, Chen Z, Dong G, Loukinova E, Pegram MY, Nicholas-Figueroa L, Van Waes C (1998) The host environment promotes the development of primary and metastatic squamous cell carcinomas that constitutively express proinflammatory cytokines IL-1alpha, IL-6, GM-CSF, and KC. Clin Exp Metastasis 16(7): 655CrossRefPubMed Smith CW, Chen Z, Dong G, Loukinova E, Pegram MY, Nicholas-Figueroa L, Van Waes C (1998) The host environment promotes the development of primary and metastatic squamous cell carcinomas that constitutively express proinflammatory cytokines IL-1alpha, IL-6, GM-CSF, and KC. Clin Exp Metastasis 16(7): 655CrossRefPubMed
12.
Zurück zum Zitat Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith CW, Enamorado I, Yeh NT, Kroog GS, Rudy S, McCullagh, Mousa S, Quezado M, Herscher LL, Van Waes C (1999) Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 5:1369PubMed Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith CW, Enamorado I, Yeh NT, Kroog GS, Rudy S, McCullagh, Mousa S, Quezado M, Herscher LL, Van Waes C (1999) Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 5:1369PubMed
13.
Zurück zum Zitat Van Waes C, Chen Z, Callister M, Colon I, Ortiz N, Smith C, Thomas GR, Dong G (2000) Cytokines in the immune pathogenesis and therapy of head and neck cancer. In: Veldman JE, Passali D, Lim DJ (eds) New frontiers in immunobiology. Kugler, Netherlands, p 233 Van Waes C, Chen Z, Callister M, Colon I, Ortiz N, Smith C, Thomas GR, Dong G (2000) Cytokines in the immune pathogenesis and therapy of head and neck cancer. In: Veldman JE, Passali D, Lim DJ (eds) New frontiers in immunobiology. Kugler, Netherlands, p 233
14.
Zurück zum Zitat Woodworth C, McMullin E, Iglesias M, Plowman G (1995) Interleukin 1 α and tumor necrosis factor a stimulate autocrine amphiregulin expression and proliferation of human papillomavirus-immortalized and carcinoma-derived cervical epithelial cells. Proc Natl Acad Sci U S A 92:2840PubMed Woodworth C, McMullin E, Iglesias M, Plowman G (1995) Interleukin 1 α and tumor necrosis factor a stimulate autocrine amphiregulin expression and proliferation of human papillomavirus-immortalized and carcinoma-derived cervical epithelial cells. Proc Natl Acad Sci U S A 92:2840PubMed
15.
Zurück zum Zitat Stevenson FT, Turck J, Locksley RM, Lovett DH (1997) The N-terminal propiece of interleukin 1 α is a transforming nuclear oncoprotein. Proc Natl Acad Sci U S A 94:508CrossRefPubMed Stevenson FT, Turck J, Locksley RM, Lovett DH (1997) The N-terminal propiece of interleukin 1 α is a transforming nuclear oncoprotein. Proc Natl Acad Sci U S A 94:508CrossRefPubMed
16.
Zurück zum Zitat Loukinova E, Dong G, Enamorado I, Thomas GR, Chen Z, Schreiber H, Van Waes C (2000) Growth regulated oncogene-alpha expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC receptor-2 dependent mechanism. Oncogene 19(31):3477PubMed Loukinova E, Dong G, Enamorado I, Thomas GR, Chen Z, Schreiber H, Van Waes C (2000) Growth regulated oncogene-alpha expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC receptor-2 dependent mechanism. Oncogene 19(31):3477PubMed
17.
Zurück zum Zitat Pak A, Wright M, Matthews J, Collins S, Petruzzelli G, Young M (1995) Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34+ cells, which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor 1. Clin Cancer Res 1:95PubMed Pak A, Wright M, Matthews J, Collins S, Petruzzelli G, Young M (1995) Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34+ cells, which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor 1. Clin Cancer Res 1:95PubMed
18.
Zurück zum Zitat Cheng X, Lopez DM (1998) CD4+, but not CD8+, T cells from mammary tumor-bearing mice have a down-regulated production of IFN-gamma: role of phosphatidyl serine. J Immunol 160(6):2735PubMed Cheng X, Lopez DM (1998) CD4+, but not CD8+, T cells from mammary tumor-bearing mice have a down-regulated production of IFN-gamma: role of phosphatidyl serine. J Immunol 160(6):2735PubMed
19.
Zurück zum Zitat Thomas GR, Chen Z, Enamorado I, Bancroft C, Van Waes C (2000) IL-12 and IL-2 induced tumor regression in a new murine model of oral squamous cell carcinoma is promoted by expression of the CD80 co-stimulatory molecule and interferon-γ. Int J Cancer 86:368PubMed Thomas GR, Chen Z, Enamorado I, Bancroft C, Van Waes C (2000) IL-12 and IL-2 induced tumor regression in a new murine model of oral squamous cell carcinoma is promoted by expression of the CD80 co-stimulatory molecule and interferon-γ. Int J Cancer 86:368PubMed
20.
Zurück zum Zitat DeVita VT, Hellman S, Rosenberg SA (eds) (1995) Biologic therapy of cancer. Lippincott, Philadelphia DeVita VT, Hellman S, Rosenberg SA (eds) (1995) Biologic therapy of cancer. Lippincott, Philadelphia
21.
Zurück zum Zitat Blankenstein T, Rowley, DA, Schreiber H (1991) Cytokines and cancer: experimental systems. Curr Opin Immunol 3(5):694 Blankenstein T, Rowley, DA, Schreiber H (1991) Cytokines and cancer: experimental systems. Curr Opin Immunol 3(5):694
22.
Zurück zum Zitat Paul WE (ed) (1993) Fundamental immunology, 3rd edn. Raven Press, New York Paul WE (ed) (1993) Fundamental immunology, 3rd edn. Raven Press, New York
23.
Zurück zum Zitat Wolf JS, Chen Z, Dong G, Sunwoo JB, Bancroft CC, Capo DE, Yeh NT, Mukaida N, Van Waes C (2001) IL (interleukin)-1alpha promotes nuclear factor-kappa B and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas. Clin Cancer Res 7(6):1812PubMed Wolf JS, Chen Z, Dong G, Sunwoo JB, Bancroft CC, Capo DE, Yeh NT, Mukaida N, Van Waes C (2001) IL (interleukin)-1alpha promotes nuclear factor-kappa B and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas. Clin Cancer Res 7(6):1812PubMed
24.
Zurück zum Zitat Young MR, Wright MA, Lozano Y, Prechel MM, Benefield J, Leonetti JP, Collins SL, Petruzzelli GJ (1997) Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells. Int J Cancer 74(1):69PubMed Young MR, Wright MA, Lozano Y, Prechel MM, Benefield J, Leonetti JP, Collins SL, Petruzzelli GJ (1997) Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells. Int J Cancer 74(1):69PubMed
25.
Zurück zum Zitat Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Oliviero B, Fogli M, Ferri E, Della Cuna GR, Tura S, Baccarani M, Lemoli RM (2002) Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 100(1):230CrossRefPubMed Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Oliviero B, Fogli M, Ferri E, Della Cuna GR, Tura S, Baccarani M, Lemoli RM (2002) Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 100(1):230CrossRefPubMed
26.
Zurück zum Zitat Jennings R, Munoz-Antonia T, Zhu Z, Jackson R, Antonia S (1999) Identification of an enhancer element in the mouse B7–1 promoter. Immunogenetics 50:109CrossRefPubMed Jennings R, Munoz-Antonia T, Zhu Z, Jackson R, Antonia S (1999) Identification of an enhancer element in the mouse B7–1 promoter. Immunogenetics 50:109CrossRefPubMed
27.
Zurück zum Zitat Foss DL, Zilliox MJ, Murtaugh MP (1999) Differential regulation of macrophage interleukin-1 (IL-1), IL-12, and CD80-CD86 by two bacterial toxins. Infect Immun 67(10):5275PubMed Foss DL, Zilliox MJ, Murtaugh MP (1999) Differential regulation of macrophage interleukin-1 (IL-1), IL-12, and CD80-CD86 by two bacterial toxins. Infect Immun 67(10):5275PubMed
28.
Zurück zum Zitat Stack RM, Lenschow DJ, Gray GS, Bluestone JA, Fisher FW (1994) IL-4 treatment of small splenic B cells induces co-stimulatory molecules B7-1 and B7-2. J Immunol 152:5723PubMed Stack RM, Lenschow DJ, Gray GS, Bluestone JA, Fisher FW (1994) IL-4 treatment of small splenic B cells induces co-stimulatory molecules B7-1 and B7-2. J Immunol 152:5723PubMed
29.
Zurück zum Zitat Hatcock KS, Laszlo G, Pucillo C, Linsley P, Rodes RJ (1994) Comparative analysis of B7-1 and B7-2 co-stimulatory ligands: expression and function. J Exp Med 180:631PubMed Hatcock KS, Laszlo G, Pucillo C, Linsley P, Rodes RJ (1994) Comparative analysis of B7-1 and B7-2 co-stimulatory ligands: expression and function. J Exp Med 180:631PubMed
30.
Zurück zum Zitat Caux C, Massacrier C, Vanberviet B, Dubois B, Van Kooten C, Durand I, Banchereau J (1994) Activation of human dendritic cells through CD40 cross-linking. J Exp Med 180:1263PubMed Caux C, Massacrier C, Vanberviet B, Dubois B, Van Kooten C, Durand I, Banchereau J (1994) Activation of human dendritic cells through CD40 cross-linking. J Exp Med 180:1263PubMed
31.
Zurück zum Zitat Ranheim EA, Kipps TJ (1995) Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40L. Cell Immunol 161:226CrossRefPubMed Ranheim EA, Kipps TJ (1995) Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40L. Cell Immunol 161:226CrossRefPubMed
32.
Zurück zum Zitat Friedman AS, Freeman GJ, Rhynhart K, Nadler LM (1991) Selective induction of B7/BB1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. Cell Immunol 137:429PubMed Friedman AS, Freeman GJ, Rhynhart K, Nadler LM (1991) Selective induction of B7/BB1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. Cell Immunol 137:429PubMed
33.
Zurück zum Zitat Schreiber H, Wu TH, Nachman J, Kast WM (2002) Immunodominance and tumor escape. Semin Cancer Biol 12:35 Schreiber H, Wu TH, Nachman J, Kast WM (2002) Immunodominance and tumor escape. Semin Cancer Biol 12:35
Metadaten
Titel
Cytokines IL-1α, IL-6, and GM-CSF constitutively secreted by oral squamous carcinoma induce down-regulation of CD80 costimulatory molecule expression: restoration by interferon γ
verfasst von
Giovana R. Thomas
Zhong Chen
Elena Leukinova
Carter Van Waes
Judy Wen
Publikationsdatum
01.01.2004
Verlag
Springer-Verlag
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 1/2004
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-003-0433-4

Weitere Artikel der Ausgabe 1/2004

Cancer Immunology, Immunotherapy 1/2004 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.